Scripps Cancer Center's 40th Annual Conference: Clinical Hematology & Oncology 2020
Immunotherapy for Advanced Stage TNBC: Modest Response with Monotherapy, Atezolizumab + Nab-Paclitaxel for PD-L1+ Disease, & Pembrolizumab May Gain FDA Approval
Login to view comments.
Click here to Login
Breast Cancer Updates